By David Cassak
Think about it this way. When John Brown took over as CEO of Kalamazoo, MI-based Stryker Corp. , Jimmy...
Few things have remained the same over the past 25 or 30 years--except John Brown's leadership at Stryker. Over the past 27 years, he's built this small Midwestern device company into a powerhouse in orthopedics and one of the industry's most consistent performers. In this interview, Brown looks back on his career, on the things that made Stryker a success, and on what it means to run a public company for nearly 30 years.
By David Cassak
Think about it this way. When John Brown took over as CEO of Kalamazoo, MI-based Stryker Corp. , Jimmy...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.